Veena Kohli

Short Bio

Veena Kohli is a renowned name in the Diagnostic Industry, with years of path breaking experience at different operational roles. She is a very passionate and a seasoned professional. She loves to share her experience with young startups and help them in their entrepreneurial journey.
She is the CEO, Vanguard Diagnostics (P) Ltd., President, ADMI (Association of Diagnostics Manufacturers of India), Chairperson, CLIN LAB India, 2019 & 2020, Convenor, IVD subgroup at the Bureau of Indian Standards (BIS), Technical Representative for IVD from India for the 22nd Asian Harmonization Working Party by Central Drugs Standard Control Organization (CDSCO), Ministry of Health & Family Welfare, GOI.
An accomplished, award-winning leader in Medical Diagnostics, she has a proven track record of leading global businesses, setting up companies and nurturing talent into senior management positions. With 30+ years’ experience, she has led global teams encompassing the entire value chain of capabilities – from R&D to Manufacturing, Quality, Supply Chain, to Marketing to Business Management – Domestic & Global.
An alumnus of the All India Institute of Medical Sciences (AIIMS), New Delhi, her professional portfolio includes senior leadership roles, with blue chip organizations like Ranbaxy Laboratories Limited, Ranbaxy Fine Chemicals Limited, RFCL and Avantor Performance Materials (USA) and Vanguard Diagnostics. She is strongly driven by the thought of making India self-reliant in the field of in vitro Diagnostics. She decided to make her contribution towards this goal, by setting up a modern manufacturing company, in the heart of New Delhi, to develop, manufacture and supply high quality diagnostics tools. Founded Vanguard Diagnostics (P) Limited in February, 2015, in order to contribute to better and affordable healthcare in India.
She spearheaded the following achievements by forming a bridge between the Govt. of India and the Diagnostic Industry
Rationalization of GST rates from 18% to 12% for diagnostics reagents.
Risk based classification of IVD products under the New Medical Devices Rules, 2017.
Formulation of vertical Standards for the first time for diagnostics products while being the convenor of the IVD subgroup at the Bureau of India Standards(BIS).